The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Thiazolidinediones and insulin resistance: Peroxisome proliferatoractivated receptor γ activation stimulates expression of the CAP gene
Open accessAbstract
c-Cbl-associated protein (CAP) is a signaling protein that interacts with both c-Cbl and the insulin receptor that may be involved in the specific insulin-stimulated tyrosine phosphorylation of c-Cbl. The restricted expression of CAP in cells metabolically sensitive to insulin suggests an important potential role in insulin action. The expression of CAP mRNA and proteins are increased in 3T3-L1 adipocytes by the insulin sensitizing thiazolidinedione drugs, which are activators of the peroxisome proliferator-activated receptor γ (PPARγ). The stimulation of CAP expression by PPARγ activators results from increased transcription. This increased expression of CAP was accompanied by a potentiation of insulin-stimulated c-Cbl tyrosine phosphorylation. Administration of the thiazolidinedione troglitazone to Zucker ( fa / fa ) rats markedly increased the expression of the major CAP isoform in adipose tissue. This effect was sustained for up to 12 weeks of treatment and accompanied the ability of troglitazone to prevent the onset of diabetes and its complications. Thus, CAP is the first PPARγ-sensitive gene identified that participates in insulin signaling and may play a role in thiazolidinedione-induced insulin sensitization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Schoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173
Martin, G., Schoonjans, K., Lefebvre, A.-M., Staels, B., & Auwerx, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.45.28210 · Cited by 551
Cited by
Insulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326
Self-citationPeroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,086
(1998) · PubMed · Cited by 2,737
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816
PPARs and the complex journey to obesity
Evans, R. M., Barish, G. D., & Wang, Y.-X. (2004) · Nature Medicine · doi:10.1038/nm1025 · Cited by 1,602
Signaling pathways in insulin action: molecular targets of insulin resistance
Pessin, J. E., & Saltiel, A. R. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10582 · Cited by 939
Self-citationMinireview: Lipid Metabolism, Metabolic Diseases, and Peroxisome Proliferator-Activated Receptors
Lee, C.-H., Olson, P., & Evans, R. M. (2003) · Endocrinology · doi:10.1210/en.2003-0288 · Cited by 890
Protein–protein interaction in insulin signaling and the molecular mechanisms of insulin resistance
Virkamäki, A., Ueki, K., & Kahn, C. R. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6609 · Cited by 854
The role of peroxisome proliferator-activated receptors (PPAR) in immune responses
Christofides, A., Konstantinidou, E., Jani, C., & Boussiotis, V. A. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154338 · Cited by 720
New Perspectives into the Molecular Pathogenesis and Treatment of Type 2 Diabetes
Saltiel, A. R. (2001) · Cell · doi:10.1016/s0092-8674(01)00239-2 · Cited by 692
Self-citationBays, H., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030723 · Cited by 664
CAP defines a second signalling pathway required for insulin-stimulated glucose transport
Baumann, C. A., Ribon, V., Kanzaki, M., Thurmond, D. C., Mora, S., Shigematsu, S., Bickel, P. E., Pessin, J. E., & Saltiel, A. R. (2000) · Nature · doi:10.1038/35025089 · Cited by 661
Self-citationNuclear Receptors and the Control of Metabolism
Francis, G. A., Fayard, E., Picard, F., & Auwerx, J. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142528 · Cited by 636
Insulin signaling pathways in time and space
Saltiel, A. R., & Pessin, J. E. (2002) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02207-3 · Cited by 628
Self-citationPPARs: Fatty acid sensors controlling metabolism
Poulsen, L. L. C., Siersbæk, M., & Mandrup, S. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.01.003 · Cited by 510
Peroxisome proliferator-activated receptors: insight into multiple cellular functions
Escher, P., & Wahli, W. (2000) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(99)00231-6 · Cited by 491
Insulin signaling in health and disease
Saltiel, A. R. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142241 · Cited by 446
“SORBS1 expression correlates well with insulin responsiveness and increases when cells are treated with insulinsensitizing thiazolidinediones (66, 107).”
BackgroundSelf-citationPPARγ AND G LUCOSE H OMEOSTASIS
Picard, F., & Auwerx, J. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.010402.102808 · Cited by 411
Retinoid X Receptor Heterodimers in the Metabolic Syndrome
Shulman, A. I., & Mangelsdorf, D. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043590 · Cited by 380
Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial
Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H., & Perrillo, R. P. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02025.x · Cited by 369
Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases
Monsalve, F. A., Pyarasani, R. D., Delgado-Lopez, F., & Moore-Carrasco, R. (2013) · Mediators of Inflammation · doi:10.1155/2013/549627 · Cited by 354
The Protein Kinase IKKɛ Regulates Energy Balance in Obese Mice
Chiang, S.-H., Bazuine, M., Lumeng, C. N., Geletka, L. M., Mowers, J., White, N. M., Ma, J.-T., Zhou, J., Qi, N., Westcott, D., et al. (2009) · Cell · doi:10.1016/j.cell.2009.06.046 · Cited by 344
Self-citationPrevention of pancreatic cancer induction in hamsters by metformin
Schneider, M. B., Matsuzaki, H., Haorah, J., Ulrich, A., Standop, J., Ding, X., Adrian, T. E., & Pour, P. M. (2001) · Gastroenterology · doi:10.1053/gast.2001.23258 · Cited by 327
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Chen, H., Tan, H., Wan, J., Zeng, Y., Wang, J., Wang, H., & Lu, X. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108391 · Cited by 311
Tamori, Y., Masugi, J., Nishino, N., & Kasuga, M. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2045 · Cited by 294
Regulation of Glucose Transporter Translocation in Health and Diabetes
Bogan, J. S. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060109-094246 · Cited by 279
Dysfunctional fat cells, lipotoxicity and type 2 diabetes
Defronzo, R. A. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2004.00389.x · Cited by 236
Regional differences of insulin action in adipose tissue: insights from in vivo and in vitro studies
Giorgino, F., Laviola, L., & Eriksson, J. W. (2005) · Acta Physiologica Scandinavica · doi:10.1111/j.1365-201x.2004.01385.x · Cited by 230
Metadata
- Authors
- Ribon, V., Johnson, J. H., Camp, H. S., & Saltiel, A. R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1998-12-08
- Volume
- 95
- Issue
- 25
- Pages
- 14751-14756
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2024682491
- Cited by
- 196
- References
- 3
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.